Counterfeit Ovulen-21 case
Executive Summary
According to FDA's March/April Case News the last defendent in the counterfeiting case, Sheldon Harwin, was sentenced on May 1 in Miami Federal Court to "11 consecutive years of incarceration." On March 14, Harwin was found guilty on five counts, which include conspiracy, causing the printing of counterfeit labels, and distribution of a counterfeit drug, FDA said. A total of seven persons have been prosecuted by FDA for distributing counterfeit Ovulen-21, the agency said. Two other defendents that were found guilty in 1987 are serving sentences of 24 years apiece ("The Pink Sheet" Dec. 5, 1988, T&G-17).
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.